GlassScriptPhysician profile
Matthew M Glick
NPI 1285694489
$12,439.71
in general payments reported to CMS, 2019-2025
65 companies · $1,982 in 2025
The $1,982 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,395 · 2020: $1,063 · 2021: $1,332 · 2022: $1,650 · 2023: $2,011 · 2024: $2,007 · 2025: $1,982.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,920 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,919.57 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,667.61 | 2019-2025 | |
| Novo Nordisk INC | $1,487.86 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Medtronic Minimed, INC. | $871.97 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $811.98 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $720.94 | 2019-2025 | |
| Astellas Pharma US INC | $603.98 | 2022-2025 | Veozah |
| Lilly USA, LLC | $512.67 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $498.55 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $492.66 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $441.19 | 2021-2024 | Rexulti |
| Amgen INC. | $337.97 | 2019-2025 | Prolia, Evenity, Otezla |
| Sanofi-Aventis U.S. LLC | $323.90 | 2019-2025 | |
| Glaxosmithkline, LLC. | $284.77 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Antares Pharma, INC. | $270.52 | 2020-2025 | Xyosted, Tlando, Nocdurna |
| Merck Sharp & Dohme LLC | $248.81 | 2019-2025 | Belsomra, Capvaxive, Gardasil 9 |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Glick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.